New obesity drug duo tested for safety in 96 volunteers
NCT ID NCT06345066
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 29 times
Summary
This early-stage study tested whether adding a new drug (LY3841136) to an existing weight-loss medication (tirzepatide) is safe and tolerable. It involved 96 healthy overweight or obese adults and lasted up to 42 weeks. The main goal was to check for side effects, not to measure weight loss directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
-
Fortrea Clinical Research Unit
Madison, Wisconsin, 53704, United States
Conditions
Explore the condition pages connected to this study.